- Home
- AGIO
as 12-20-2024 4:00pm EST
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 2.4B | IPO Year: | 2013 |
| Target Price: | $56.33 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 11.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $20.96 - $62.58 | Next Earning Date: | 02-13-2025 |
| Revenue: | $32,871,000 | Revenue Growth: | 36.79% |
| Revenue Growth (this year): | 33.38% | Revenue Growth (next year): | 163.06% |
Stock Insider Trading Activity of Agios Pharmaceuticals Inc. (AGIO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Washburn Theodore James Jr. | AGIO | Principal Accounting Officer | Nov 8 '24 | Sell | $56.09 | 772 | $43,301.48 | 813 | |
| Burns James William | AGIO | Chief Legal Officer | Nov 7 '24 | Sell | $52.28 | 21,752 | $1,135,774.96 | 24,041 | |
| Ballal Rahul D. | AGIO | Director | Nov 7 '24 | Sell | $56.55 | 20,000 | $1,117,146.69 | 9,492 | |
| Jones Cecilia | AGIO | Chief Financial Officer | Sep 26 '24 | Sell | $49.03 | 2,542 | $124,634.26 | 20,158 |
Latest Agios Pharmaceuticals Inc. News
AGIO Breaking Stock News: Dive into AGIO Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Agios Pharmaceuticals Says Mitapivat Granted EU Orphan Drug Status for Sickle Cell Disease
GlobeNewswire
4 days ago
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease
Zacks
12 days ago
Here's Why Agios Stock Plummeted More Than 20% on Monday
TipRanks
12 days ago
Agios Pharmaceuticals price target raised to $75 from $53 at Scotiabank
MT Newswires
12 days ago
RBC Raises Price Target on Agios Pharmaceuticals to $57 From $55, Keeps Outperform Rating
Investor's Business Daily
12 days ago
Agios Crashes 21% After A Surprise Side Effect Hammered Its 'Very Safe' Drug
MT Newswires
13 days ago
Agios Pharmaceuticals Meets Phase 3 Primary, Secondary Goals
GlobeNewswire
13 days ago
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
Compare AGIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AGIO Agios Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.